- Home
- STX vs NVO Comparison
STX vs NVO Comparison
Compare STX & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STX | NVO |
|---|---|---|
| Founded | 1978 | 1923 |
| Country | Singapore | Denmark |
| Employees | N/A | 69500 |
| Industry | Electronic Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.2B | 197.4B |
| IPO Year | 2002 | N/A |
Fundamental Metrics
Financial Performance| Metric | STX | NVO |
|---|---|---|
| Price | $911.62 | $47.66 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 21 | 11 |
| Target Price | ★ $604.14 | $51.00 |
| AVG Volume (30 Days) | 3.5M | ★ 11.9M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | 0.46% | ★ 3.19% |
| EPS Growth | ★ 328.48 | N/A |
| EPS | ★ 8.29 | N/A |
| Revenue | ★ $7,384,000,000.00 | N/A |
| Revenue This Year | $27.73 | N/A |
| Revenue Next Year | $25.06 | $3.70 |
| P/E Ratio | $123.38 | ★ $13.60 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $138.31 | $35.12 |
| 52 Week High | $1,145.00 | $71.80 |
Technical Indicators
Market Signals| Indicator | STX | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 48.70 | 65.41 |
| Support Level | $801.89 | $47.52 |
| Resistance Level | $966.80 | $47.79 |
| Average True Range (ATR) | 71.82 | 1.32 |
| MACD | -9.29 | 0.47 |
| Stochastic Oscillator | 29.81 | 87.39 |
Price Performance
Historical ComparisonAbout STX Seagate Technology Holdings PLC (Ireland)
Seagate Technology is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital; they are both vertically integrated.
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.